Indications
Istradefylline is indicated in adults as an adjunctive treatment to levodopa based regimens in patients with Parkinson’s disease (PD) experiencing “OFF” time.
Composition
- Active substance
- Istradefylline
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nouryant
- Active substance
- Istradefylline
- ATC code
- N04
- Group
- Nervous system
- Therapeutic area
- Parkinson Disease
- Marketing authorisation holder
- Kyowa Kirin Holdings B.V.
- Status
- Refused
- Refused
- 6 Jan 2022
- EMA product number